Anavex Life Sciences Corp (AVXL)

[F1ash]

Observed adverse events at doses above the maximum tolerated single dose included headache and dizziness, which were moderate in severity and reversible.

75 neurological AE’s at 57 weeks and only 13 at 148 weeks. Must have reduced dosing or the folks with headaches dropped out?

Through 57 weeks, Alzheimer’s patients taking a daily oral dose between 10mg and 50mg of ANAVEX®2-73 was well tolerated. There were no clinically significant treatment-related adverse events and no serious adverse events.



Strange because the supplements to the latest paper seem to indicate 5 SAE’s at 57 weeks and either 6 or 9 at 148 weeks. Not clear if they were treatment related but doesn’t matter because they appear to be stating there were none at all. ????